Targeting the mitogen-activated protein kinase cascade to treat cancer.
The RAS-mitogen activated protein kinase (MAPK) signalling pathway has long been viewed as an attractive pathway for anticancer therapies, based on its central role in regulating the growth and survival of cells from a broad spectrum of human tumours. Small-molecule inhibitors designed to target various steps of this pathway have entered clinical trials. What have we recently learned about their safety and effectiveness? Will the MAPK pathway prove amenable to therapeutic intervention?
Sebolt-Leopold
Judith S
JS
Molecular Sciences and Technologies, Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA. Judith.Leopold@pfizer.com
Herrera
Roman
R
D002453:Cell Cycle; D002455:Cell Division; D002470:Cell Survival; D004789:Enzyme Activation; D006801:Humans; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*; D008958:Models, Molecular; D009369:Neoplasms / Q000473:pathology / Q000628:therapy*; D011487:Protein Conformation; D015398:Signal Transduction
D020928:Mitogen-Activated Protein Kinases